prikaz prve stranice dokumenta Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
  Preuzmi
PDF 1.16 MB
Znanstveni rad - Izvorni znanstveni rad
Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
Journal of Oncology, 2020 (2020); 6423936. https://doi.org/10.1155/2020/6423936
Majić, Ana; Miše, Branka Petrić; Matković, Višnja; Belac-Lovasić, Ingrid; Katić, Kristina; Canjko, Ivana; Frobe, Ana; Bajić, Žarko; Vrdoljak, Eduard

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Majić, A., Miše, B. P., Matković, V., Belac Lovasić, I., Katić, K., Canjko, I. ... Vrdoljak, E. (2020). Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study. Journal of Oncology, 2020.. doi: 10.1155/2020/6423936

Majić, Ana, et al. "Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study." Journal of Oncology, vol. 2020, 2020. https://doi.org/10.1155/2020/6423936

Majić, Ana, Branka Petrić Miše, Višnja Matković, Ingrid Belac Lovasić, Kristina Katić, Ivana Canjko, Ana Frobe, Žarko Bajić i Eduard Vrdoljak. "Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study." Journal of Oncology 2020 (2020). https://doi.org/10.1155/2020/6423936

Majić, A., et al. (2020) 'Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study', Journal of Oncology, 2020. doi: 10.1155/2020/6423936

Majić A, Miše BP, Matković V, Belac Lovasić I, Katić K, Canjko I, i sur.. Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study. Journal of Oncology [Internet]. 20.06.2020. [pristupljeno 22.11.2024.];2020. doi: 10.1155/2020/6423936

A. Majić, et al., "Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study", Journal of Oncology, vol. 2020, Lipanj 2020. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:589476. [Citirano: 22.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:589476
Podaci o radu
Naslov (engleski)Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
AutorAna Majić
AutorBranka Petrić Miše
AutorVišnja Matković
AutorIngrid Belac-Lovasić
AutorKristina Katić
AutorIvana Canjko
AutorAna Frobe
AutorŽarko Bajić
AutorEduard Vrdoljak
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za onkologiju i radioterapiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Onkologija
Sažetak (engleski)
Our objective was to assess the safety and efficacy of olaparib in maintenance therapy of BRCA 1-2 mutated, platinum-sensitive, recurrent ovarian carcinoma after the partial or complete response to the second or further lines platinum-based chemotherapy in a real-world setting. We performed a multicenter, real-world observational population-based cohort study on the whole population of Croatian patients initiated to olaparib maintenance therapy between 2016 and 2020. The primary endpoints were progression-free survival and the discontinuation of treatment because of adverse events. We enrolled the total population of 69 patients with the median (interquartile range; IQR) age of 53 (48–59), 56 (81%) of them with BRCA1 mutation. The median (IQR) follow-up was 16 (9–25) months. Treatment had to be discontinued because of toxicity in 2 (3%) and temporarily interrupted in 14 (20%), while dose was reduced because of toxicity in 18 (26%) of patients. Toxicity of any grade was observed in 61 (88%) patients and toxicity of grade 3 or 4 in 12 (17%). Median progression-free survival was 21 (95% CI 16-not calculable) months from the introduction of olaparib, and the median overall survival was not reached. Our study confirmed efficacy and safety of olaparib as the maintenance therapy of BRCA 1-2 mutated, platinum-sensitive, recurrent ovarian carcinoma. We observed the real-world efficacy and safety comparable to those observed in the randomized controlled trials. We found the interesting observation of better efficacy of 300 mg tablets, compared to 400 mg capsules, an issue that should be addressed on much larger real-world populations.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Oncology
Brojčani podacivol. 2020, 6423936
p-ISSN1687-8450
e-ISSN1687-8469
DOIhttps://doi.org/10.1155/2020/6423936
URN:NBNurn:nbn:hr:184:589476
Datum objave publikacije2020-06-20
URL dokumentahttps://www.hindawi.com/journals/jo/2020/6423936/
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2020-11-10 20:31:47